ORIGINAL ARTICLE

Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand

Francisco C Pérez-Martínez¹, Verónica Alonso¹, José L Sarasa¹, Syon-Ghyun Nam-Cha², Remigio Vela-Navarrete¹, Félix Manzarbeitia¹, Francisco J Calahorra¹ and Pedro Esbrit¹

¹ Fundación Jiménez Díaz (Grupo Capio), Madrid, Spain
² Hospital Universitario de Albacete, Albacete, Spain

Correspondence to:
Correspondence to:
DrF C Pérez-Martínez
Fundación Jiménez Díaz (Grupo Capio), Avda Reyes Católicos, 28040 Madrid, Spain; fcpmartinez{at}hotmail.com

Aim: To investigate multiple bone cytokines produced by prostate carcinoma (PCa) as a novel strategy to differentiate potential aggressiveness in localised PCa using immunohistochemical analysis.

Methods: A total of 47 cases of PCa undergoing radical prostatectomy or transurethral prostatic resection at our institution (Fundación Jiménez Díaz (Grupo Capio), Madrid, Spain) between January 1991 and June 1998 were identified as low-grade (4; n = 22) or high-grade (7, excluding 7 (3+4) cases; n = 25) PCa according to Gleason grade. PCa specimens were immunostained for: parathyroid hormone (PTH)-related protein (PTHrP), the PTH1 receptor, osteoprotegerin and receptor activator of nuclear factor- B ligand (RANKL), as well as Ki67 (a proliferation marker) and CD34 (an angiogenesis marker).

Results: PCa samples showed an increased immunostaining for both osteoprotegerin and RANKL, associated with tumour grade and PTHrP positivity, in the tumoral epithelium. Using a score value of 4—corresponding to moderate staining—as cut-off, the best sensitivity value was for PTHrP (with C-terminal antiserum C6; 100 %); wheras the best specificity value was for RANKL (95 %).

Conclusions: All the evaluated factors are overexpressed mainly in the high-grade tumours. Our findings indicate that, in most patients with PCa (with Ki67 values between 1% and 9%), sequential determination of C-terminal PTHrP and RANKL immunoreactivities is a useful approach to discriminate low-grade and high-grade tumours.

Abbreviations: OPG, osteoprotegerin; PCa, prostate carcinoma; PTH, parathyroid hormone; PTH1R, PTH1 receptor; PTHrP, PTH-related protein; RANKL, receptor activator of nuclear factor- B ligand

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Berruti, A., Tucci, M., Mosca, A., Ardine, M., Poggio, M., Saini, A., Russo, L., Vana, F., Dogliotti, L. (2008). Could the Efficacy of Docetaxel in Prostate Cancer Patients Be Potentiated by Concomitant High-Dose Calcitriol Administration?. JCO 26: 1900-1901 [Full Text]  
• Schwartz, G. G. (2008). Prostate Cancer, Serum Parathyroid Hormone, and the Progression of Skeletal Metastases. Cancer Epidemiol. Biomarkers Prev. 17: 478-483 [Abstract] [Full Text]